Personality disorders Reference Sleep and mental health 
Psychiatric Times
JUNE 24, 2025
A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. SHOW MORE What is a sleep disorder?
Psychiatric Times
JULY 11, 2025
References 1. Most of our agents that we talk about as mood stabilizers may be effective in preventing a manic episode or treating mania or mixed states,” Maguire said. Our options are more limited when it comes to bipolar depression, and we do have some agents that are FDA approved specifically for bipolar depression.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JULY 8, 2025
An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. References 1. points (effect size 0.61) in study 501 and 4.5 points (effect size 0.56) vs placebo in study 502. Supplemental new drug application submitted to U.S.
Psychiatric Times
JULY 1, 2025
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.” 3 References 1. June 30, 2025.
Psychiatric Times
JUNE 23, 2025
The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. We remain focused on our goal of transforming the landscape of mental health treatment.” References 1. points (95% CI [-5.7, -1.5]) in change at the primary endpoint. News release.
Psychiatric Times
JUNE 23, 2025
1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.
Psychiatric Times
JUNE 13, 2025
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately. References 1. BMC Psychiatry. Schonecker M.
Expert insights. Personalized for you.
84 
Let's personalize your content